These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 17010732)

  • 1. Tumor characteristics and prognostic factors in two subsequent screening rounds with four-year interval within prostate cancer screening trial, ERSPC Rotterdam.
    van der Cruijsen-Koeter IW; Roobol MJ; Wildhagen MF; van der Kwast TH; Kirkels WJ; Schröder FH
    Urology; 2006 Sep; 68(3):615-20. PubMed ID: 17010732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC)--Section Rotterdam. A comparison of two rounds of screening.
    Postma R; Schröder FH; van Leenders GJ; Hoedemaeker RF; Vis AN; Roobol MJ; van der Kwast TH
    Eur Urol; 2007 Jul; 52(1):89-97. PubMed ID: 17257742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam.
    Roobol MJ; Grenabo A; Schröder FH; Hugosson J
    J Natl Cancer Inst; 2007 Sep; 99(17):1296-303. PubMed ID: 17728218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No reason for immediate repeat sextant biopsy after negative initial sextant biopsy in men with PSA level of 4.0 ng/mL or greater (ERSPC, Rotterdam).
    Roobol MJ; van der Cruijsen IW; Schröder FH
    Urology; 2004 May; 63(5):892-7; discussion 897-9. PubMed ID: 15134973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of screen detected and clinically diagnosed prostate cancer in the European randomized study of screening for prostate cancer, section rotterdam.
    van der Cruijsen-Koeter IW; Vis AN; Roobol MJ; Wildhagen MF; de Koning HJ; van der Kwast TH; Schröder FH
    J Urol; 2005 Jul; 174(1):121-5. PubMed ID: 15947595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC.
    Schröder FH; Bangma CH; Roobol MJ
    Eur Urol; 2008 May; 53(5):901-8. PubMed ID: 18262712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).
    Roobol MJ; Kranse R; de Koning HJ; Schröder FH
    Urology; 2004 Feb; 63(2):309-13; discussion 313-5. PubMed ID: 14972478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).
    Roobol MJ; Roobol DW; Schröder FH
    Urology; 2005 Feb; 65(2):343-6. PubMed ID: 15708050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potentially advanced malignancies detected by screening for prostate carcinoma after an interval of 4 years.
    Postma R; Roobol M; Schröder FH; van der Kwast TH
    Cancer; 2004 Mar; 100(5):968-75. PubMed ID: 14983492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 4-year prostate specific antigen progression and diagnosis of prostate cancer in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
    Schröder FH; Raaijmakers R; Postma R; van der Kwast TH; Roobol MJ
    J Urol; 2005 Aug; 174(2):489-94; discussion 493-4. PubMed ID: 16006878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumour features in the control and screening arm of a randomized trial of prostate cancer.
    Postma R; van Leenders AG; Roobol MJ; Schröder FH; van der Kwast TH
    Eur Urol; 2006 Jul; 50(1):70-5. PubMed ID: 16434136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.
    Zhu X; van Leeuwen PJ; Bul M; Otto SJ; de Koning HJ; Bangma CH; Schröder FH; Roobol MJ
    Eur Urol; 2011 Aug; 60(2):330-6. PubMed ID: 21601352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lesions predictive for prostate cancer in a screened population: first and second screening round findings.
    Postma R; Roobol M; Schröder FH; van der Kwast TH
    Prostate; 2004 Nov; 61(3):260-6. PubMed ID: 15368469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positive predictive value of prostate biopsy indicated by prostate-specific-antigen-based prostate cancer screening: trends over time in a European randomized trial*.
    Bokhorst LP; Zhu X; Bul M; Bangma CH; Schröder FH; Roobol MJ
    BJU Int; 2012 Dec; 110(11):1654-60. PubMed ID: 23043563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atrophy in prostate needle biopsy cores and its relationship to prostate cancer incidence in screened men.
    Postma R; Schröder FH; van der Kwast TH
    Urology; 2005 Apr; 65(4):745-9. PubMed ID: 15833520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of the digital rectal examination in subsequent screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rotterdam.
    Gosselaar C; Roobol MJ; Roemeling S; Schröder FH
    Eur Urol; 2008 Sep; 54(3):581-8. PubMed ID: 18423977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma.
    Hugosson J; Aus G; Lilja H; Lodding P; Pihl CG
    Cancer; 2004 Apr; 100(7):1397-405. PubMed ID: 15042673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical progression rates in the screen arm compared to the control arm of the Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Roemeling S; Roobol MJ; Gosselaar C; Schröder FH
    Prostate; 2006 Jul; 66(10):1076-81. PubMed ID: 16637077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Schröder FH
    Can J Urol; 2005 Feb; 12 Suppl 1():2-6; discussion 92-3. PubMed ID: 15780157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Towards an optimal interval for prostate cancer screening.
    van Leeuwen PJ; Roobol MJ; Kranse R; Zappa M; Carlsson S; Bul M; Zhu X; Bangma CH; Schröder FH; Hugosson J
    Eur Urol; 2012 Jan; 61(1):171-6. PubMed ID: 21840117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.